Investival Showcase - GMT (Greenwich Mean Time, GMTZ)
2025 has been a year of economic uncertainty amid a changing geopolitical and macroeconomic stress. Our panel of investment experts discuss how Europe is responding to the global challenges and how we can make Europe a fertile ground for innovation.
Europe’s current state, opportunities, strengths and challenges
Addressing the persisting early-stage funding gaps and how to meet the high bar for financing
China as a rising force – how does Europe & US compare?
The Impact of AI and digital health on investment patterns across regions
Strategies for European companies to attract global investment
The past 18 months have seen a shift in life sciences M&A, with fewer deals at higher values being completed. Here experts will explore the reasons for the shift and how to best position your company for a fair and efficient acquisition.
Latest M&A trends in life sciences
Factors affecting deal valuation
Strategies to attract strategic buyers
With the IPO boom of 2020 and 2021 leaving investors burnt by falling share prices there has been scepticism surrounding taking life science companies public. Join us as our panel discuss when and how to consider an IPO to provide the greatest chances of success in the public market.
IPO readiness and timing
Pros and cons of the European and US public markets
Post-IPO considerations and investor relations
SPAC opportunities and alternative listing routes
The US has long been considered the place to be in the life sciences space given the market size and more attractive investment and reimbursement landscapes. Join US market access experts as they discuss the changing US political landscape and how to find success across the pond.
Accessing US capital markets
Strategic partnerships with American investors
The importance of having US based stakeholders and how to lead a transatlantic team
Navigating FDA requirements for European companies
The AI revolution is no longer a pipe dream, artificial intelligence is providing a palpable difference to life science companies from startups to multinational corporations and investors are taking notes. We hear from life science investors and their thoughts on AI incorporation and how it is changing the investment process.
Investor perspectives on AI-driven investment opportunities
Valuation metrics for AI-enabled life science companies
Risk assessment in AI-focused investments
The so called “valley of death” between early and late-stage funding continues to prove a critical risk to life science companies. With venture capital funds unable to support the entire industry on their own, alternative funding sources are on the rise. Learn more about the differences between traditional and novel funding sources and what is best for your company.
Structured financing options, royalty financing and venture debt
How private equity differs from traditional VC funding
Strategic partnerships and licensing deals
Recent reports have highlighted the evolving role of large strategics in powering innovation in life science. With a possible shift away from internal R&D, big pharma and tier 1 medtechs are looking for external innovation to drive growth in their business units. Join our panel of CVC leaders as they discuss their process and rationale for investment and strategies for getting in front of these global giants.
Strategic vs. financial investment approaches
CVC investment criteria and focus areas
Building successful CVC partnerships
Recent years have seen a real terms decrease in VC investment into the life sciences sector. The pandemic bubble burst with returns not as fruitful as anticipated leading to a new wave of caution among investors. Here, we hear from real life examples of de-risking investment opportunities and strategies to best position your company for investment.
The most common pitfalls in early-stage startups
How to derisk your investment proposition
Successful series A raising case studies
Successfully raising series A financing is cause for celebration in the current investment climate. However, for successful companies this will be the first of many successes and milestones. The next step once series A funding has been secured is instrumental in the long-term strategy of the company, CEOs should consider further funding rounds, capital markets and deal making when evaluating what comes next.
What different growth and scaling routes look like in practice
Further funding rounds, IPO, or acquisition?
How to know which route is best for you
Strategy and milestones are crucial factors for investors and stakeholders. These milestones and their timelines can often be affected by unforeseen circumstances, in such cases companies can seek bridge financing to extend their runway and increase chances of an exit. Our panel of investors share their thoughts on bridge financing, when it is needed and best practices for securing additional funding.
Bridge financing, what is it and when should it be sought
Pros and cons of bridge financing
Investor opinion on funding to extend runways
Getting your medtech funded is not for the faint of heart, less funding rounds, high interest rates, and relatively few specialist investors. Though difficult, raising money is not impossible. Hear from our panel of investors and executives on what makes an attractive investment and how best to position your company for funding.
The due diligence process on medtech companies
Most valuable information on a pitch deck
The valuation correction and its impact
TechBio and digital transformation are staking their claim in the life science sector. Investment in life sciences AI and deeptech is up significantly following the popularisation of large language models and increased usage in day-to-day life, however there is growing scepticism from investors given the lack of case studies generating significant returns on investment. Our panel of investors give their thoughts and discuss what might be next for TechBio.
Importance of AI and machine learning in life science
The value proposition for final acquirers
Supporting frontline innovation without an ROI blueprint